REVIEW: Virus-Associated Human Tumors: Cervical Carcinomas and Papilloma
Viruses
F. L. Kisseljov
Institute of Carcinogenesis, Blokhin Russian Cancer Research Center,
Kashirskoe Shosse 24, Moscow, 115478 Russia; fax: (7-095) 323-5733;
E-mail:
f.kis@cityline.ru
Received September 17, 1999
The latest experimental data on the role of viruses in the origin of
human tumors are discussed. This group of viruses consists of T-cell
leukemia virus type 1 (HTLV 1), herpes viruses (HHV 8 and Epstein--Barr
virus), hepatitis B virus, and human papilloma viruses. The most
typical feature of this group of viruses is a very long latent period
from the initial infection to the development of the disease that
varies between 10 and 40 years. The mechanism of malignant cell
conversion is specific for each viral type but is mainly associated
with a disruption of functions of cellular genes participating in the
control of cell division and proliferation. It can be a direct
inactivation of tumor suppressor genes by their interaction with viral
gene products (papilloma viruses), or a trans-activation of cellular
genes modulating cell proliferation by viral gene products (hepatitis B
virus and HTLV 1). Viruses play an initiative role and additional
genetic changes in the genome of infected cells are necessary for
complete expression of the oncogenic potential of the viral genes. Only
these cells will give rise to a monoclonal cell population with
uncontrolled proliferation. New approaches for the creation of vaccines
against cancers associated with hepatitis B virus and papilloma viruses
(hepatocellular carcinomas and cervical tumors, respectively) are in
progress. These vaccines have been found to be effective in prevention
of the disease in the experimental models and are now beginning to be
used for human vaccination.
KEY WORDS: tumors, cervical cancer, transformation, mechanisms,
papilloma viruses, transforming genes, oncogenes, tumor suppressor
genes